Arkadios Wealth Advisors Sells 52 Shares of Stryker Co. (NYSE:SYK)

Arkadios Wealth Advisors lessened its stake in Stryker Co. (NYSE:SYK) by 7.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 680 shares of the medical technology company’s stock after selling 52 shares during the period. Arkadios Wealth Advisors’ holdings in Stryker were worth $245,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SYK. Dale Q Rice Investment Management Ltd bought a new stake in shares of Stryker in the 4th quarter worth approximately $587,000. PFW Advisors LLC acquired a new position in shares of Stryker in the fourth quarter valued at $1,350,000. Parnassus Investments LLC bought a new position in Stryker in the third quarter worth $762,798,000. Baltimore Washington Financial Advisors Inc. boosted its stake in Stryker by 2.4% during the third quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock worth $24,089,000 after buying an additional 1,554 shares in the last quarter. Finally, Sivik Global Healthcare LLC increased its holdings in Stryker by 8.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after buying an additional 2,000 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.8 %

SYK stock opened at $393.79 on Friday. The business has a fifty day moving average of $375.82 and a 200-day moving average of $360.16. The company has a market cap of $150.12 billion, a P/E ratio of 42.21, a PEG ratio of 2.72 and a beta of 0.95. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.46 EPS. As a group, equities research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s payout ratio is currently 36.01%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on SYK shares. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Royal Bank of Canada restated an “outperform” rating and set a $425.00 price target on shares of Stryker in a research note on Tuesday, January 7th. Barclays upped their price objective on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Wells Fargo & Company raised their target price on Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their price target on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.